FRANKFURT — A shareholder now controls at least 3% of the voting rights in Bayer Aktiengesellschaft, the German pharmaceutical and crop science giant, after surpassing the threshold on an unspecified recent date.

The filing, submitted under Germany’s Securities Trading Act (WpHG), details the position but omits the exact name of the shareholder acquiring the stake. Section 3 of the notification identifies the person subject to the reporting obligation, while section 4 notes any direct holders of 3% or more voting rights, if distinct from the filer.

According to section 5, the threshold crossing occurred on a specific date not publicly detailed in the summary release. Total positions outlined in section 6 break down the holdings as follows: voting rights tied to shares under sections 33 and 34 of the WpHG fall under subsection 7a. Financial instruments qualifying under section 38(1) no. 1 WpHG appear in 7b.1, and those under section 38(1) no. 2 WpHG in 7b.2.

Section 8 provides further information on the notifying party, though specifics remain limited in the public notice. No proxy voting details under section 34 para. 3 WpHG appear in section 9, indicating no attribution of rights via general meeting proxies under section 34 para. 1 sent. 1 No. 6.

Bayer, listed under ticker DE000BAY0017 on the Frankfurt Stock Exchange, faces ongoing scrutiny over its holdings and investor moves amid legal battles from its 2018 Monsanto acquisition. That $63 billion deal saddled the company with massive litigation costs from Roundup weedkiller lawsuits, wiping out billions in market value since.

Threshold crossings like this one often signal activist investor interest or portfolio adjustments by funds. BlackRock and other major asset managers already rank among Bayer’s top shareholders, with stakes exceeding 5% in recent filings. This new 3% holder could join that group, depending on the exact percentage reached.

Regulatory filings serve as early warnings for potential influence on corporate decisions, from dividend policies to executive pay. Bayer’s annual general meeting typically reviews such positions, but this notice makes no reference to a specific meeting date or post-AGM holdings.

Company shares traded flat in recent sessions around €28 per share, reflecting steady but pressured performance. Investors watch these disclosures closely, as clustered ownership changes can foreshadow boardroom shakeups or strategic shifts.

BaFin, Germany’s financial regulator, mandates these reports within four trading days of a threshold breach at 3%, 5%, 10% and higher levels. The filing adds transparency to Bayer’s shareholder base, now totaling millions of shares outstanding with free float above 70%.

Details emerge from the ad-hoc disclosure platform, standard for such notifications in Europe’s major markets. Bayer has not commented publicly on the investor’s identity or intentions.